Reviewing Strategic Investment Criteria

Landscape

• Disciplined approach in place to make thoughtful acquisitions

• Opportunities exist across all three life sciences market segments

• All 3 remaining core businesses in fragmented markets that are consolidating

1. On Strategy

2. NPV/Accretive value

3. Management team in place tosuccessfully integrate

Strengthens our core businesses

Broadens our capabilities to serve customers better

Improves positioning in our markets

Offers tangible synergies

Investment Approach

Use disciplined financial analysis

No diversification beyond remaining 3 core businesses

Criteria for selection:

Product Portfolio Spans Research andDrug Discovery Workflow

• Diverse product portfolio

• Broad customer relationships

• Leading market position

API 3200

API 4000

ELAN DRC

API 5000

API 4000

4800 MALDI

TOF/TOF

4000 QTRAP

MetaMorph

SpectraMax

FLIPR

IonWorks

CellKey

ImageXpress

TransFluor

Axopatch

PatchXpress

Laser Capture

Microdissection

Basic

ResearchScreening

Lead

Optimization SafetyClinical

Trials

Applied

Markets

Molecular Devices: A Platform for Growth

• Blue chip customer base across pharmaceutical, biotech, academic and government laboratories

• Strong reputation for quality and innovation

• Installed base of 100,000 instruments

• Products: < $100K price points

• Leader in detection and imaging

• Attractive market drivers

• Products: $100 – 500K price points

• Breakthrough solutions

• Attractive market drivers

• Global sales and support infrastructure – 230 person direct sales and support

• Robust R&D engine – history of product innovation; rich pipeline

Biology Research: 60% of Revenues Drug Discovery: 40% of Revenues

• High Content Screening gaining traction

• Reagents / consumables targeting high growth applications

• Steady government funding

• Interest in biomarkers and personalized medicine